PDCD1 and hepatocellular carcinoma: De novo Development of brain-reactive autoantibodies was not associated with a specific neoplasm (four cases of melanoma, two cases of non-small cell lung cancer [NSCLC], one case of hepatocellular carcinoma), ICI type (four cases with nivolumab treatment [PD-1 inhibitor], three cases with atezolizumab treatment [PD-L1 inhibitor]), or neurological symptoms.